DNA Group (TR) (XTAE:DNA) Debt-to-EBITDA : 0.00 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is DNA Group (TR) Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

DNA Group (TR)'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪0.00 Mil. DNA Group (TR)'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪0.00 Mil. DNA Group (TR)'s annualized EBITDA for the quarter that ended in Dec. 2023 was ₪-2.39 Mil. DNA Group (TR)'s annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for DNA Group (TR)'s Debt-to-EBITDA or its related term are showing as below:

XTAE:DNA's Debt-to-EBITDA is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.3
* Ranked among companies with meaningful Debt-to-EBITDA only.

DNA Group (TR) Debt-to-EBITDA Historical Data

The historical data trend for DNA Group (TR)'s Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DNA Group (TR) Debt-to-EBITDA Chart

DNA Group (TR) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.18

DNA Group (TR) Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of DNA Group (TR)'s Debt-to-EBITDA

For the Biotechnology subindustry, DNA Group (TR)'s Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DNA Group (TR)'s Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DNA Group (TR)'s Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where DNA Group (TR)'s Debt-to-EBITDA falls into.

DNA Group (TR) Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

DNA Group (TR)'s Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-2.174
	=	0.00

DNA Group (TR)'s annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-2.388
	=	0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

DNA Group (TR) (XTAE:DNA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

DNA Group (TR) Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of DNA Group (TR)'s Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.